Drugs / BIIB094
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03976349 | Aug 2019 → Aug 2024 | Parkinson disease | Ionis Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BIIB094 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03976349 ↗ |
| Known as | ION859 | “BIIB094 (ION859), an antisense oligonucleotide, targets LRRK2 mRNA for degradation.” PMID 41876647 ↗ Mar 2026 |
| Modality | Antisense oligonucleotide | “BIIB094 (ION859), an antisense oligonucleotide, targets LRRK2 mRNA for degradation.” PMID 41876647 ↗ Mar 2026 |
| Target | LRRK2 | “targets LRRK2 mRNA for degradation.” PMID 41876647 ↗ Mar 2026 |